Transthyretin amyloidosis cardiomyopathy in patients with HFpEF in Russia - TETRAMER

Study identifier:D8450R00006

ClinicalTrials.gov identifier:NCT06338839

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

multicenter observational retrospective-prospective study of prevalence and clinical characteristics of transthyretin amyloidosis cardiomyopathy in Russian patients with heart failure with preserved ejection fraction in real clinical practice

Medical condition

Transthyretin amyloidosis cardiomyopathy, heart failure with preserved ejection fraction

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1770

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 28 Dec 2023
Estimated Primary Completion Date: 30 Nov 2024
Estimated Study Completion Date: 30 Nov 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria